Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Jun 01, 2023

SELL
$7.54 - $10.04 $173,744 - $231,351
-23,043 Closed
0 $0
Q1 2022

May 18, 2022

BUY
$6.0 - $16.98 $138,258 - $391,270
23,043 New
23,043 $151,000
Q1 2022

May 16, 2022

SELL
$6.0 - $16.98 $106,758 - $302,125
-17,793 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$15.19 - $29.33 $270,275 - $521,868
17,793 New
17,793 $292,000

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $881M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.